dx.doi.org/10.1038/d41586-025-01503-3

Preview meta tags from the dx.doi.org website.

Linked Hostnames

26

Thumbnail

Search Engine Appearance

Google

https://dx.doi.org/10.1038/d41586-025-01503-3

Migraine drug is first to tackle debilitating early symptoms

Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent pre-headache fatigue and light sensitivity.



Bing

Migraine drug is first to tackle debilitating early symptoms

https://dx.doi.org/10.1038/d41586-025-01503-3

Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent pre-headache fatigue and light sensitivity.



DuckDuckGo

https://dx.doi.org/10.1038/d41586-025-01503-3

Migraine drug is first to tackle debilitating early symptoms

Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent pre-headache fatigue and light sensitivity.

  • General Meta Tags

    49
    • title
      Migraine drug is first to tackle debilitating early symptoms
    • title
      Close banner
    • title
      Close banner
    • charset
      utf-8
    • X-UA-Compatible
      IE=edge

  • Open Graph Meta Tags

    5
    • og:url
      https://www.nature.com/articles/d41586-025-01503-3
    • og:type
      article
    • og:title
      Migraine drug is first to tackle debilitating early symptoms
    • og:description
      Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent pre-headache fatigue and light sensitivity.
    • og:image
      https://media.nature.com/lw1200/magazine-assets/d41586-025-01503-3/d41586-025-01503-3_50971630.jpg

  • Twitter Meta Tags

    5
    • twitter:site
      @nature
    • twitter:title
      Migraine drug is first to tackle debilitating early symptoms
    • twitter:description
      Nature - Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent pre-headache fatigue and light sensitivity.
    • twitter:image
      https://media.nature.com/lw1200/magazine-assets/d41586-025-01503-3/d41586-025-01503-3_50971630.jpg
    • twitter:card
      summary_large_image

  • Item Prop Meta Tags

    4
    • position
      1
    • position
      2
    • position
      3
    • publisher
      Springer Nature

  • Link Tags

    15
    • apple-touch-icon
      /static/images/favicons/nature/apple-touch-icon-f39cb19454.png
    • canonical
      https://www.nature.com/articles/d41586-025-01503-3
    • icon
      /static/images/favicons/nature/favicon-48x48-b52890008c.png
    • icon
      /static/images/favicons/nature/favicon-32x32-3fe59ece92.png
    • icon
      /static/images/favicons/nature/favicon-16x16-951651ab72.png

Emails

1
  • ?subject=Migraine drug is first to tackle debilitating early symptoms&body=https%3A%2F%2Fwww.nature.com%2Farticles%2Fd41586-025-01503-3

Links

111